Product

Tirabrutinib

Aliases

ONO-4059, ONO/GS-4059

2 clinical trials

3 indications

Indication

B-cell Lymphoma

Indication

Primary Central Nervous System Lymphoma

Indication

Primary CNS Lymphoma

Clinical trial

A Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib (ONO/GS-4059) in Combination With Other Targeted Anti-cancer Therapies in Subjects With B-cell Malignancies

Status: Active (not recruiting), Estimated PCD: 2025-12-01

Clinical trial

An Open-label Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Tirabrutinib in Patients With Primary Central Nervous System Lymphoma (PCNSL)

Status: Recruiting, Estimated PCD: 2027-03-31